NYSE · BIO.B
Bio – Rad Laboratories, Inc.
$309.37 +$10.87 (+3.64%) 1D
Session Pulse
Pre-market
1
mentions on Fri
· 1 bullish
/ 0 bearish tags
No new SEC filings since Mon close
its sector ranked
9/11
this week
Full pulse →
Key Metrics
$8.65B
Market cap
51.24×
P/E · TTM
$2.59B
Revenue · TTM
$168.80M
Net income
EPS · TTM
$6.04
Dividend yield
—
Free cash flow
$357.20M
Beta · 1Y
—
EBITDA · TTM
—
Gross margin
51.9%
Snapshot
Market cap—
Enterprise value$2.57B
Shares outstanding26.8M
52-wk range$244.54 – $321.12
Avg volume · 20D538
Net cash
$6.07B
Book value / share$245.08
IndustryLaboratory Analytical Instruments
ExchangeNYSE
About Bio – Rad Laboratories, Inc.
IPO dateJan 1, 1900
Employees7450
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E51.24
P/S3.34
P/FCF24.21
EV/EBITDA—
EV/Sales0.99
Graham №$182.48
Profitability
Gross
51.9%
Operating
8.6%
Net
6.5%
FCF
13.8%
ROE / ROIC
2.5% · 2.8%
Financial Health
Current ratio3.21
Quick ratio2.37
Debt / equity0.12
Debt / EBITDA
—
Net cash
$6.07B
Working capital$2.03B
Cash Flow · TTM
Operating CF
$510.40M
Capex
−$153.20M
Free cash flow
$357.20M
Buybacks
$241.40M
Dividends paid
—
Shareholder yield
2.8%
Piotroski F-Score
4 / 9
Middling fundamentals · 4 of 9 signals passing
Altman Z-Score
3.4
Safe zone (> 2.99) · bankruptcy risk negligible
Graham Number vs Price
$182.48 vs $309.37
Trades 1.7× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings